It has been demonstrated that a subpopulation of CD133+ pancreatic cancer cells have CSCs characteristics and are highly chemo-resistance (2) Therefore, a suitable anticancer compound should be able to diminish CSCs as well as other cancer populations. This evidence concerns the gene PROM1 and pancreatic neoplasm.